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Abstract 
This report was prepared by Gonçalo André and Tomás Branco, two Master in Finance 
students of Nova School of Business and Economics (“Nova SBE”), within the context 
of the Field Lab – Equity Research. The goal was to evaluate Johnson & Johnson’s 
intrinsic value. Therefore, a thorough analysis of its operating segments and industries 
was conducted. Our valuation model resulted in a share price of $166.00, which led to 
the conclusion that J&J is trading below its fair value. In addition, it was measured how 
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We initiate our coverage with a BUY recommendation. We value 
J&J at $166.00, meaning total upside potential of 17%. We expect 
the company to show strong results in its pharmaceutical and 
medical devices sector, ousting uncertainty on recent opioid and 
baby powder litigations. 
Oncology driving J&J’s growth  
We expect the oncology division to be the main driver of J&J’s 
growth, with sales evolving at a CAGR of 11.8% and representing 
17% of total sales by 2023. Darzalex
®
 to grow 13.7% YoY and 
Imbruvica
®
 to grow at 12.8%. 
Current pipeline enough to outperform 
Operational forecast leads to the conclusion that J&J’s current 
pipeline would be enough to ensure future strong performance. In 
a scenario in which nearly-approved drugs do not get approved, 
J&J would still be trading at a discount. This scenario leads to a 
target price of $155.56, above current market price.  
Valuation 
Our target price of $166.00 is based on a DCF model (WACC of 
6.34% and terminal growth of 3.26%), with expected return of 17%. 
In a bullish scenario, upside potential is 24%. Main risks regard the 
settlement of current litigations and the possibility of future law 
suits. 
Company description 
Johnson & Johnson is a U.S. based healthcare company engaged 
in researching, developing and selling pharmaceutical products, 
consumer healthcare goods and medical devices. In 2018 
revenues accounted for roughly $81.6bn. 
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(dollars in billions except per 
share amounts) 
2018 2019E 2020F 
Revenues 81.6 82.7 85.7 
EBITDA 26.7 25.1 26.0 
EBITDA margin 32.8% 30.4% 30.3% 
EBIT 19.8 18.3 18.7 
Net Profit 14.0 15.5 16.5 
EPS 5.6 5.8 6.2 
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Founded in 1886, in New Jersey, by Johnson brothers, Johnson & Johnson (J&J) 
started its activity being the first company to produce cotton white, sterile and 
absorbent for surgery purposes, breaking through the surgical care industry. 134 
years later,  J&J is one of the biggest companies in the healthcare industry, 
engaged in research and development, manufacture and sale of products. It 
employs more than 130,000 people worldwide. 
J&J’s activities are divided into three different segments: pharmaceutical, medical 
devices (MD) and consumer products, reporting revenues from U.S and 
international operations. In 2018, the pharmaceutical segment accounted for c. 
half of J&J’s total revenues, 49.9% ($40.7bn), while MD and consumer products 
accounted for 33.1% ($27.0bn) and 17.0% ($13.8bn), respectively. Total sales 
amounted to $81.6bn. During the 1
st
 nine months of 2019, pharmaceutical, 
medical devices and consumer revenues were $31.7bn, $19.3bn and $10.3bn, 
respectively, adding up to $61.3bn of total revenues. As such, we expect J&J to 
generate around $82.6bn in FY 2019. 
Pharmaceutical 
J&J engages in researching and developing drugs to address some of the most 
devastating diseases. Drugs produced are sold and distributed to hospitals, 
medical care professionals and retailers, for prescription use. The segment is 
divided in six different areas: immunology, infectious diseases, neuroscience, 
oncology, pulmonary hypertension (PH) and cardiovascular/metabolism. In 2019, 
sales are expected to be $42.7bn, meaning a 5.0% growth year-on-year (YoY). 
Immunology is the main driver of pharmaceutical revenue, representing 32.4% 
of the segment’s revenue ($13.1bn) and having grown 7.2% in 2018. In 2019 is 
expected to generate sales of $14.1bn, meaning a growth of 7.7%. Remicade
®
, 
J&J’s best-selling drug for the last 5 years, is used for treating immunological 
diseases such as rheumatoid arthritis, ulcerative colitis or Chron’s disease. As a 
consequence of the Food and Drug Administration’s (FDA) approvals for the 
production of biosimilars in 2016 (which resulted in J&J losing its Remicade
®
 
patent in 2018), Remicade
®
 sales have been decreasing in the last two years. In 
2018, sales decreased by 15.6%. The increasing number of biosimilars entering 
the market will significantly impact future sales – we expect a decrease from 
$5.3bn in 2018 to about $4.4bn in 2019, representing a fall of 18.1%. However, 
immunology sales have been increasing, mostly due to J&J’s second best-selling 
drug, Stelara
®
, which accounted for $5.2bn, increasing 28% in 2018. Due to 
further R&D developments, during 2019, an extension to treat patients suffering 
Exhibit 1.  Revenue breakdown by 
segment (2018) 
Exhibit 2. Revenue breakdown by 
geography (2018) 
Exhibit 3. Pharmaceutical revenue 
breakdown by division (2018)  












from Ulcerative Colitis was approved in the E.U. (still filed for approval in the 
U.S., showing good clinical results). In addition, an extension to be used in 
patients with Pediatric Psoriasis, was filed. Therefore, we expect Stelara
®
 sales 
to continue growing. In 2019, revenue should grow 25.6%.  
Oncology accounted for 24.3% of total segment’s revenue ($9.8bn), growing 
35.6% from 2017 to 2018. This growth was mostly supported by Darzalex
®
, due 
to the increasing number of patients with multiple myeloma and J&J’s market 
share expansion, resulting in sales growth 63.0%. Growth was also driven by 
Imbruvica
® 
gaining market share, with revenues growing 38.1% and by Zytiga
®
 
sales growing by 39.6%, as a consequence of an increasing market for prostate 
cancer drugs and LATITUDE findings regarding Zytiga
®
’s Active Pharmaceutical 
Ingredient (API). Although at a slower pace, the oncology division is expected to 
continue growing, as in 2019: two new extensions to Darzalex
®
 approved in the 
U.S. and filed for approval in the E.U.; two extensions to Imbruvica
®
 approved 
both in the U.S. and E.U.; and two New Molecular Entities (NMEs) approved in 
the U.S. – Erleada
®
, used on metastatic castrate sensitive prostate cancer and 
Balversa
TM
, used on urothelial cancer. Together with the increase of the market 
for oncology drugs, J&J’s revenue is expected to grow 11.7% in 2019. 
Neuroscience represents 15.0% of the segment’s sales, growing 1.5% in 2018, 
from $6.0bn to $6,1bn, following 3 years with decreasing sales. This was mostly 
due to Invega
®
 drugs sales growth. In the first three quarters of 2019, sales 
amounted to $4.8bn, expected to be $6.4bn by year-end. Growth in 2019 is 
mostly because of the increasing market for mood disorders drugs (growing 
11.8% YoY) and the launch of a NME, Spravato
TM
. 
As for the remaining three divisions, cardiovascular/metabolism/other sales 
decreased from 2017 to 2018 by 7.5%. This was mainly due to the decrease in 
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approved in the U.S., are not likely to overcome the continuous decrease of both 
market shares. On the other hand, infectious diseases sales increased 4.8% 
from 2017 to 2018, being expected to grow 2.6% by the end of 2019. Pulmonary 
hypertension, a reporting segment established in June 2017, following the 
acquisition of Actelion, reported full year sales for the first time in 2018, which 
amounted to $2.6bn. In 2019 revenues are expected to reach $2.7bn, (5.4% YoY 
growth), as a result of Opsumit
®
’s extension approved in the U.S.. 
Pharmaceutical activity highly depends on pipeline performance and patents 
protecting intellectual property. The future impact of both in J&J’s valuation is 
further discussed on this report. 
LATITUDE findings: according to 
cancerNetwork, home of the journal 
Oncology, the combination of 
abiraterone acetate plus prednisone 
along with androgen deprivation 
therapy resulted in significantly longer 
survival for patients. 
Exhibit 5. Oncology revenue (2017 - 
2019)  
Exhibit 6. Neuroscience revenue (2017 - 
2019)  
Exhibit 7. Cardiovascular, infectious 
diseases, PH revenue (2017 - 2019)  
 
 









The MD segment is, in terms of revenue, J&J’s 2
nd
 largest segment. It is 
responsible for the research, production and sale of medical devices, that are 
distributed to wholesalers, healthcare providers and hospitals around the world. 
The segment is divided in diabetes care, interventional solutions, orthopaedics, 
surgery supplies and vision care. In 2014 the diagnosis division was divested, 
reporting sales until 2017, which referred to a transactional services agreement, 
concluded in that same year. In 2018, MD revenues grew by 1.5%, amounting to 
$27.0bn and representing 33.1% of J&J’s total revenues. Until the 3
rd
 quarter of 
2019, revenues were $19.3bn and are expected to be around $26.0bn by year-
end, decreasing 3.7% YoY. This poor performance can be explained by recent 
divestitures and by the loss of market share in orthopaedics and surgery. 
Surgery sales increased 3.6% from 2017 to 2018, being the largest division in 
MD. Nonetheless, we expect this increase to be reverted, with a decrease of 
3.5% in sales by the end of 2019. J&J is being negatively affected, as 
competitors are selling digital surgery robots. With the acquisition of Auris in April 
2019 (surgery robots) and because of the success of gastric and thoracic surgery 
innovation (endocutter stapler), we expect surgery’s sales to recover from 2020 
onwards, as it is further discussed in the revenue drivers’ section. 
Orthopaedics revenue, following the trend of the last years, decreased by 1.9% 
between 2017 and 2018, as a consequence of recent divestitures. Orthopaedics 
is divided in four divisions: hips, knees, trauma and spine & other. During 2018, 
spine & other sales decreased due to the divestiture of Codman Neurosurgery 
and market share loss due to digital surgery robots, as they are used in spine 
interventions. Sales in knees division also decreased, consequence of 
competitive pressure on U.S. prices. In 2019, revenues are expected to continue 
decreasing, at -0.9% YoY, as J&J’s orthopaedics segment will keep being 
affected by not having implemented digital robot surgeries. However, as in 
surgery, from 2019 onwards, we expect sales to recover and grow (see valuation 
chapter). 
Vision segment experienced growth of 12.1% in 2018 (16.9% of 2018 revenues). 
Between 2016 and 2017 sales grew 45.9%. The segment reports sales from two 
different divisions: contact lenses and surgical. Recent growth is consequence of 
three factors: the continuous growth in contact lenses and related products’ 
revenues under Acuvue brand – the top-selling contact lenses brand; the 
reallocation of vision surgery revenues from the surgical division to the vision 
one, in 2017; and cataract surgery’s performance outside the US. We expect the 
Exhibit 8. Medical devices revenue 
breakdown by division (2018) 
Exhibit 9. Surgery revenue (2017-2019) 
Exhibit 10. Orthopaedics revenue (2017-
2019) 
Exhibit 11. Vision revenue (2017-2019) 
 
 








trend to be maintained in 2019, at a slower pace, with revenue growing 1.8%, 
mostly supported by increasing market share in contact lenses.  
Regarding interventional solutions, sales grew 15.2% on 2018, mostly due to 
market growth for Atrial Fibrillation procedure and continued uptake from 
previously launched Contact Force Sensing Catheter. In 2019 we expect sales to 
increase 13.4%, continuing to benefit from market growth.  
Diabetes care division, representing 3.7% of total medical devices sales, 
decreased by 37.5% in 2018. This decrease was consequence of J&J’s 
divestiture of Animas and Lifescan. With this, J&J completed the sale of its 
diabetes care portfolio. 
The results of J&J’s MD segment are highly correlated with the launch of new 
products and the ability of competitors to do so, as well. Our thought on the 
impact on J&J’s future results is further discussed on the drivers’ chapter. 
Consumer Goods 
Consumer goods is J&J’s smallest reporting segment. It is responsible for the 
development and marketing of many well-known household products, sold to 
distributors and retailers around the globe. Consumer products are divided in six 
different areas: baby care, beauty, oral care, over-the-counter (OTC), women’s 
health and wound care. In 2018, consumer sales grew by 1.8% from 2017, 
amounting to $13.9bn. In the 1
st
 nine months of 2019 it reported revenues of 
$10.3bn and is expected to achieve $13.8bn by the end of the year (YoY growth 
of 0.1%). Low growth in this segment results from decreasing sales in baby care, 
women health and wound care.  
Beauty sub-segment, the main revenue driver within the segment, represented 
31.6% of total sales. This division has been facing growth in the last years, 
mostly due to an increasing market for beauty products, mainly in emerging 





 and Dr.CI: Labo products, whose international market share grew 
by 1.9%, overcoming the decrease in U.S.’ market share by 1.16%. In 2019 we 
expect this upward trend to continue, with sales growing 5.2%. 
OTC sales accounted for 31.3% of the segment’s revenue in 2018. It is the 
division showing higher growth, as sales grew by 5.0% in 2018, supported by: 
growth of 4.0% in the market for OTC products, mostly outside the U.S.; increase  







acquisition of Zarbee’s Inc. (that made OTC sales grow 0.9%). In 2019, sales are 
expected to continue growing, for the same reasons, around 2%.  
Exhibit 12. Interventional solutions 
revenue (2017-2019) 
Exhibit 13. Consumer goods revenue 
breakdown by division (2018) 
 
Exhibit 14. Beauty revenue (2017 – 2019) 
 












In 2018, Oral care sales increased by 1.6%, accounting for 11.2% of the 
segment’s total sales. Growth was mostly driven by strong marketing campaigns 
and the launch of new LISTERINE
®
 products. In 2019, sales should decrease 
1.8%, as a consequence of market share loss both in international and U.S. 
markets. However, we do not expect further revenue decreases, due to J&J’s 
strong brands within oral care, as it is further explained. 
Sales of the remaining divisions decreased in 2018. Baby care sales fell by 
3.0%, as a consequence of decreasing market for baby care products in the U.S., 
together with findings of asbestos in J&J’s baby powder products, which caused 
reputational damage and decreased the company’s market share. In 2019, 
revenues are expected to continue decreasing, by 9.5%, following consumers’ 
awareness on J&J’s baby powder case. Regarding women’s health and wound 
care divisions, sales decreased by 0.1% and 13.3%, respectively. J&J has been 
losing market share on these two markets in the past years, as products are also 
suffering from reputation damage due to baby powder litigations. As such, we 
expect sales to continue decreasing in 2019. 
Consumer Healthcare, is J&J’s smallest segment and it is expected to grow at a 
lower pace than the other segments, following J&J’s market share loss in recent 
years and most recently, due to litigations on products within the segment. 
Further impact on J&J’s future financials and valuation are discussed ahead. 
 Shareholder Structure 
Johnson & Johnson is a publicly traded company, listed in the NYSE since 1944. 
J&J’s common shares amount to 3.2bn with 457.5m being held in treasury.  
Institutional shareholders such as big pension and investment funds, hold 70.2% 
of the market’s floating stocks. Top 3 institutional shareholders are The Vanguard 
Group, Inc. (8.5%), SSgA Funds Management, Inc. (5.8%) and BlackRock Fund 
Advisors (4.9%). Moreover, 0.1% of total shares outstanding are held by insiders. 
The remaining 29.7% are free floating stocks, being traded daily on the stock 
exchange. The average trading volume for the last 3 months was 7.2m. By 
comparing free floating shares of J&J and its peers (excluding institutional 
shareholders), we were able to conclude on the volatility of J&J’s stock. As 
observed, J&J has a lower percentage of free floating shares (29.7%) than the 
average of its peers’ (37.2%). As such, J&J’s stock should be more volatile, since 
by having a lower number of shares that can be bought or sold, in case of a 
major event happening, share price will vary in higher proportions.  
 
Exhibit 16. Oral care, baby care, 
women’s health revenue (2017 – 2019) 
 
Exhibit 17. Shareholder Structure 
Exhibit 18. Peers’ shareholder structure 
 
 









By analysing J&J’s stock in the last year, we can see that legal liability and 
uncertainty regarding litigations have dominated J&J’s investment debate. In the 
beginning of December 2018, J&J’s stock was trading at a relative price 5.4% 
above S&P500. In late October 2019, after months of discussions and lawsuits 
regarding J&J’s baby powder and following the intensification on opioid talks, 
J&J’s share was trading at a relatively low record of 15.6% below the S&P500. 
After J&J’s SEC filing on the 26
th
 of October 2019, stating an agreement in 
principle to settle opioid litigation at $4.0bn, J&J’s price started recovering, going 
from $128.35 to $145.75, currently trading 10.6% below the S&P500. 
Dividend Policy 
J&J has defined a fixed policy regarding dividends, being paid on a quarterly 
basis. Dividends per share have been increasing (DPS) YoY, going from 2.8$ in 
2014, to $3.5 in 2018. This is the result of a dividend payout ratio between 47.6% 
and 62.1%. In 2017, when J&J’s net income fell by 92.1%, from $16.5bn in 2016 
to $1.3bn (due to Tax Cut and Job Act implemented in 2017) J&J’s DPS 
increased, leading to an abnormal payout ratio of 687.9%. Following that, we can 
conclude that J&J is keen in increasing its DPS, even when results decrease. 
During 2019, the four dividend payments amounted to a total of $3.75 per share. 
We expect DPS in 2020 to increase by $0.05 following past years, to $1 DPS per 
quarter. 
When comparing J&J’s dividend yield in 2018 with its peers’, we can observe that 
Johnson & Johnson’s stock is yielding a return below its peers’ average – 
dividend yield of 2.8% versus peers’ average of 3.1%. 
Industry Overview & Revenue Drivers 
In the following sections, we discuss how J&J’s market share in each segment 
has evolved and how we expect it to change. Moreover, we present our 
estimates on how the different markets will evolve and how that impacts J&J. 
Pharmaceutical 
The pharmaceutical industry is responsible for the development, production and 
marketing of medications. Between 2014 and 2018, worldwide industry sales 
recorded a CAGR of 3.7%, with annual turnover always exceeding $1.3tn. In 
2019, worldwide sales are expected to be $1.5tn, with ~19% happening in the 
U.S.. In the U.S. alone, annual turnover increased 6.2% per year, on average, 
with revenues expected to be $289.1bn in 2019. The U.S. is the leading country 
Exhibit 21. Global pharmaceutical  
market revenue (2014 – 2019)  
Source: Passport (Euromonitor)  
Exhibit 19. J&J and S&P500 returns 
(2017 – 2018) 
Exhibit 20. J&J and eers’ dividend yield 
 
 








in this market, with its companies accounting for ~47% of total sales. Yet, the 
Chinese and Brazilian pharmaceutical sectors recorded the largest growth in the 
last 5 years, growing on average 9.6% and 8.7% per year, respectively. China’s 
largest pharmaceutical company (Sinopharm Group) recorded sales growth of 
14.6%, with revenue in 2018 of $48.5bn. Such companies have been claiming a 
larger market share. However, most innovative medicines still come from the 
U.S..  
Johnson & Johnson is the 4
th
 largest global player regarding revenue, with 
turnover of $40.7 bn in 2018 and market share of ~2.7%, only surpassed by: 
Pfizer (U.S.) with market share of ~3.6%, Novartis (Switzerland) with market 
share of ~3.5% and Roche (Switzerland) with market share of ~3.0%. Regarding 
the U.S., J&J’s market share is 8.0%, with sales of $23.3 bn. Since 2015, J&J is 
the company recording the largest revenue growth, as its market share has been 
increasing, while that of Pfizer and Novartis has been decreasing. Other relevant 
players include Merck & CO (U.S.), Sanofi (France), Abbvie (U.S.) and 
GlaxoSmithKline (U.K.), all recording sales above $30bn in 2018. J&J recorded 
the largest net income in 2018 ($15.3 bn) and is the largest in terms of market 
capitalization - about $383.6bn, substantially above the 2
nd
 largest, Roche 
Holding AG with a market cap of $280.3 bn.  
Out of the four leading pharmaceutical companies, J&J has clearly the best gross 
profit margin, consistently above 81.5% in the last 5 years (83.3% on average). 
During that period, Pfizer’s average margin was 79.1%, Novartis’ 65.0% and 
Roche’s 74.2%. Even with higher production efficiency, J&J’s average EBITDA 
margin of 40.4% is below that of Pfizer (44.3%) and very close to Roche’s 
(40.6%). This is mainly due to J&J’s large R&D expenses, which is one of the 
main drivers of J&J’s value. J&J’s R&D charges are ~21.2% of total revenue, 
while Pfizer only spends ~14.8% of sales revenues in R&D. 
The pharmaceutical industry is probably the most R&D-dependent industry. As 
science develops and the investment in the treatment of rare diseases increases, 
it is expected that more innovative and effective drugs arise, which will lead to an 
industry expansion. In 2018, J&J was the world’s 2
nd
 largest spender in R&D, 
with expenses of $8.4bn in its pharmaceutical segment, which represented 
20.7% of the segment’s revenue. Roche was the largest spender, with $9.7bn in 
R&D costs. Due to all the efforts in R&D, patents play a major role in the 
pharmaceutical industry. In the U.S., patents typically last for 20 years. However, 
after a company files for a patent, the FDA’s approval may take many years. This 
means that, as the product starts to be sold, companies will have less than 20 
years of exclusivity. Yet, most of J&J’s drugs have been approved in less than a 
Exhibit 23. Gross profit margin - Pfizer, 
Novartis, Roche, J&J  
Exhibit 24. EBITDA margin - Pfizer, 
Novartis, Roche, J&J  
Exhibit 22. Global pharmaceutical 












year. Even if a drug is already on the market, companies can file for patent 
extensions and expand the drug’s medical use. Compensating the expiration of a 
certain patent with the creation of a new one (through NMEs), or the extension of 
an existing one, is crucial to ensure sustainability and growth. A study by the 
University of Groningen in July 2018
1
 determined that after a patent expires, 
prices usually go down up to 66%, five years after expiration. Moreover, a study 
by the National Bureau of Economic Research in August 2014
2
, estimated that 3 
- 5 new players usually enter the market after patent expiration, with global 
revenue actually increasing after the price drops, as a result of higher demand. 
However, profit margins decrease and global revenue is divided amongst the 
original patent owner and the new entrants. The impact of patent losses in J&J’s 
sales was estimated in accordance with these studies. 
Together with governments, the FDA, the World Health Organization (WHO) and 
the Medicines and Healthcare Products Regulatory Agency (MHRA) have been 
tightening pharmaceutical companies’ pricing strategies, as pressure for price 
decreases keeps surging. The goal is to have a balance between rewarding and 
enhancing medical innovation, while making medicines accessible for everyone. 
The U.S. president Donald Trump announced in early 2019 that he intended to 
lower drug prices in the U.S., following policies that already exist in many 
European countries. Some measures included making it more difficult for drug 
manufacturers to raise prices, while others make sure information regarding 
negotiations between firms, health insurers and pharmacy benefit managers are 
disclosed. Thus, even though U.S. drug prices are still fairly unregulated, there 
are signs of that changing in the near future. After analysing pharmaceutical 
spending in European countries with strict price regulation (Austria, Belgium, 
France, Germany, Spain, Greece, Italy and Ireland), we could conclud that drug 
prices in the U.S. are ~54% higher. As price regulation intends to make 
medicines more accessible for people, we believe that revenue will not decrease 
as prices get lower, since demand increases. Therefore, we expect gross profit 
margins of pharmaceutical companies to suffer as regulation tightens. In our 
estimates, we assume that by 2030, U.S. drug prices will be between current 
levels and European prices (meaning U.S. prices ~27% higher than in Europe). 
As a result of that, we estimate J&J’s U.S. gross profit margins to have 
decreased 3.6pps by 2030 (from 2019’s margin of 83.2%). 
The industry’s major segments are oncology, antidiabetics, respiratory and 
autoimmune diseases, which combined turnover exceeded $290bn in 2018. 
                                                 
1
 Vondeling, Gerard T; Cao, Qi; Postma, Maarten J and Rozenbaum Mark H. 2018. “The Impact of Patent Expiry on Drug Prices”. 
Applied Health Economics and Health Policy, 16(5), 653-66. 
2
 Rena, M. Conti, and Ernst R. Berndt. 2014. “Specialty drug prices and utilization after loss of U.S. patent exclusivity, 2001-2007”. 
Measuring and Modeling Health Care Costs 
Austria 646$         
Belgium 689$         
France 653$         
Germany 823$         
Greece 603$         
Ireland 599$         
Italy 601$         
Spain 598$         
U.S. 1 220$       
Exhibit 25. Pharmaceutical spending per 
capita – U.S. vs European countries  
 
 








Branded, patented medications represent the largest portion of the pharma 
industry - around 78.7% in 2018 - while unbranded generics accounted for 11.7% 
and branded generics for 9.6%. Ageing populations, driven by decreasing fertility 
rates and increased life expectancy, will drive up the demand for pharmaceutical 
products. The percentage of people over 60 years of age is expected to grow at a 
fast pace, going from ~12% in 2017 to over 16% in 2030. A study by Mercer 
Capital in 2016 found that, on average, people above 65 years of age spend 3x 
more on healthcare than other adults and 5x more than children. Thus, as 
populations get older, the average revenue per capita of pharmaceutical 
companies increases. Another factor driving the demand for pharmaceutical 
products is the growing disposable income of low and middle class families, as 
drugs become more accessible. Below we discuss our beliefs on how J&J’s 
pharmaceutical divisions will evolve. 
Immunology: estimates by EvaluatePharma state global annual sales will grow 
at 3.9% until 2023, reaching $81.2bn. We believe that afterwards, growth will 
slow down to 3.8% as a result of a decrease in dermatology’s growth rate, from  
11.4% (EvaluatePharma’s growth estimate until 2023) to 7.7%. We predict 
growth in dermatology to reduce, as opportunities to serve unmet needs through 
innovative drugs will decrease, and growth will mostly be due to increases of 
market reach. We expect annual global dermatology sales to achieve $28.7bn by 
2023. J&J serves two other immunology divisions – gastroenterology and 
rheumatology. Global rheumatology market is forecasted to expand only 0.3% 
per year until 2023, as current drugs fulfil patients’ needs, achieving $33.4bn. We 
believe growth will be the same after 2023. Worldwide gastroenterology revenue 
is forecasted to grow 1.8% per year until 2023. Even if the number of gastric 
diseases is expected to increase at 6.5%, according to Mayo Clinic, the shift 
towards surgery and bacterial transplants will continue (according to Zion Market 
Research), lowering the demand for non-post-surgery recuperation drugs. After 
that, we believe growth will increase to 2.6%, more in line with the number of 
gastric diseases. Thus, gastric global market turnover will expand from $17.5bn 
in 2018 to $19.1bn in 2023. 
J&J’s market share in the immunology market, in 2018, was 19.6%, expected to 
rise to 20.4% in 2019. This is due to Stelara
®
’s success in the gastric division, 
following an increase in sales due to an extension approval in 2016 (representing 
36.4% of global gastric drugs’ revenue) and because Tremfya
®
’s market share 
keeps increasing, after the drug’s approval in 2017. Even if we believe these 
drugs will continue to increase in sales and gain market share, we expect that the 
expiration of Remicade
®
’s patent in 2018 (J&J’s most sold drug) will ultimately 
lead to a decline in J&J’s immunology market share. We expect J&J’s market 
Exhibit 26.  Percentage of people over 60 
years of age 
Source: United Nations (2017).  
Exhibit 27. Worldwide immunology 
drugs market revenue (2018 – 2023) 
Source: J&J Investor Presentation (May, 2019).  
 
 








share to have decreased to 16.5% by 2023 and to slightly reduce afterwards, as 
we do not predict new approvals in this division, reaching 15.6% in 2030. As 
such, we expect J&J’s immunology sales to evolve as follows: 
Immunology 2018A 2019E 2020F 2021F 2022F 2023F ... 2030F
Market size ($bn) 67.1$  69.4$  72.0$  74.8$  77.8$  81.2$  ... 105.1$ 
J&J market share 19.6% 20.4% 19.1% 17.8% 17.2% 16.5% ... 15.6%
J&J revenue ($bn) 13.1$  14.1$  13.8$  13.3$  13.4$  13.4$  ... 16.4$   
Oncology: global market is expected to grow 10.1% per year until 2023, with 
hematology growing 10.4% and prostate cancer medicines growing 4.0%, 
according to EvaluatePharma’s estimates. This expansion is mainly due to the 
increasing number of new cancer cases worldwide, resulting mostly from ageing 
populations (17M cases in 2018, expected to reach 27.5M by 2040 – data from 
Cancer Research U.K.), and due to the development of new drugs to fulfil unmet 
needs. As both population ageing and drug innovation are expected to continue, 
we expect growth to slightly decrease after 2023, to 8.2%. As such, global 
oncology turnover should increase from $78.6bn in 2018 to $127.0bn in 2023. 
We believe hematology will keep growing above the remaining divisions, at a 
pace of 8.5% after 2023, as innovation should continue. Thus, global hematology 
revenue is predicted to grow from $42.0bn in 2018 to $69.0bn in 2023. As for 
prostate cancer, we believe growth will stay the same after 2023, at 4.0%, 
expanding from $9.7bn in 2018 to $11.8bn in 2023. With the introduction of 
Balversa
TM
 in 2019, J&J entered the market for urothelial cancer drugs, a 
reasonably smaller market. Yet, annual revenue is expected to experience large 
growth, reaching $2.9bn by 2023 (from $1,051m in 2018). 
With the approvals of Erleada
®
 for the treatment of prostate cancer and 
Balversa
TM
 in 2019, J&J’s share of oncology drugs’ revenue should rise to 12.7% 
in 2019 (0.2pps above 2018). We believe both drugs will experience high 
revenue growth, with Erleada
®
 sales representing 8.1% of prostate cancer drugs 
and Balversa
TM
 representing 9.0% of global urothelial cancer drugs’ market, by 
2023. We also expect recently-approved Darzalex
® 
to continue growing in sales 
and become a best-seller. Together with Imbruvica
®
, we believe these drugs may 
represent 15.6% of the hematologic market by 2023 and 16.6% by 2030. 
Therefore, we believe J&J will increase its share of global oncology drugs’ 
revenue to 13.5% by 2023 and 13.7% by 2030. All things considered, we 
estimate J&J’s oncology revenue to be: 
Oncology 2018A 2019E 2020F 2021F 2022F 2023F ... 2030F
Market size ($bn) 78.6$  86.5$  95.2$  104.8$ 115.4$ 127.0$ ... 221.1$ 
J&J market share 12.5% 12.7% 12.9% 13.1% 13.4% 13.5% ... 13.7%
J&J revenue ($bn) 9.8$    11.0$  12.3$  13.8$  15.4$  17.2$  ... 30.2$   
Exhibit 28. Worldwide oncology drugs 
market revenue (2018 – 2023) 
Source: J&J Investor Presentation (May, 2019).  
 
 








Neuroscience: according to EvaluatePharma, schizophrenia global revenue is 
expected to grow 3.3% per year, reaching $8.0bn in 2023. The disease affects 
~23m people worldwide, with most facing multiple relapses and shifting towards 
long-acting injectable medicines such as J&J’s Invega
®
, which will drive up the 
market’s total revenue. J&J joined the mood disorders market with the 
introduction of Spravato
TM
 in March 2019, a drug for adults suffering from 
depression. We believe this drug can have a large impact, since depression 
affects more than 300M people worldwide. According to the WHO, about 800k 
people suicide every year because of depression. The mood disorders market 
should grow 11.4% per year, until 2023, reaching $12.5bn, as a result of people’s 
increasing concern and as innovative drugs such as Spravato
TM
 are developed. 
Afterwards, we predict growth to slow down to 7.6%. J&J is set to enter multiple 
sclerosis market as a result of Ponesimod’s approval, which is expected to 
happen in 2021. Worldwide multiple sclerosis turnover is expected to grow 0.2%, 
reaching $23.2bn by 2023, according to iHealthcareAnalyst. We believe growth 
will be sustained afterwards. Overall, global neuroscience sales are expected to 
grow 2.9% per year, reaching $44.8bn in 2023. 
With the approval of Spravato
TM
 in 2019 and the expected approval of 
Ponesimod for treating multiple sclerosis in 2020, we expect J&J to increase its 
market share in the neuroscience division, in spite of litigations related to 
Risperdal Consta
®





8.5% of global mood disorder sales and 
Ponesimod representing 1.9% of worldwide multiple sclerosis revenue. However, 
after that, we expect J&J’s market share to decrease following patents expiration 
for Risperdal Consta
® 
in 2023 and Concerta
®
 in 2022. Following these patent 
losses, we believe J&J’s market share will gradually fall to 17.6%. Overall, we 
expect J&J’s neuroscience revenue to be as follows: 
Neuroscience 2018A 2019E 2020F 2021F 2022F 2023F ... 2030F
Market size ($bn) 38.9$  40.0$  41.2$  42.3$  43.6$  44.8$  ... 54.6$  
J&J market share 15.6% 15.9% 16.6% 17.5% 18.2% 18.2% ... 17.6%
J&J revenue ($bn) 6.1$    6.4$    6.8$    7.4$    7.9$    8.1$    ... 9.6$     
Pulmonary hypertension (PH): annual turnover is expected to increase 5.1% 
per year, until 2023, reaching $7.7bn. PH is a deadly disease with 1 out of 3 
patients dying within 5 years of diagnosis. Main reasons for the market’s 
expansion are: late diagnosis is reducing (as awareness is increasing) and 
because 2/3 of all PH patients are only using a single drug in their treatments, 
still not benefiting from the advantages of combined treatments. As such, we 
expect growth to be sustained after 2023, around 5.1%. 
Exhibit 29. Worldwide neuroscience 
drugs market revenue (2018 – 2023) 
Source: J&J Investor Presentation (May, 2019).  
Exhibit 30. Worldwide PH drugs market 
revenue (2018 – 2023) 
Source: J&J Investor Presentation (May, 2019).  
 
 








Johnson & Johnson leads the market for PH drugs, as sales in 2018 accounted 
for 42.9% of global revenue. Since J&J’s Uptravi
®
 continues to gain market 
share, we believe that until 2022, J&J will increase its total share of PH drugs 
market, to 44.5%. Yet, with the expiration of Tracleer
®
’s patent in 2022, J&J’s 
market share should gradually decrease to 43.0%. As such, we estimate J&J’s 
PH sales as: 
PH 2018A 2019E 2020F 2021F 2022F 2023F ... 2030F
Market size ($bn) 6.0$    6.3$    6.6$    7.0$    7.3$    7.7$    ... 10.9$  
J&J market share 42.9% 43.0% 43.8% 44.4% 44.5% 44.4% ... 43.0%
J&J revenue ($bn) 2.6$    2.7$    2.9$    3.1$    3.3$    3.4$    ... 4.7$     
Infectious diseases: global sales are expected to increase 2.8% per year as a 
result of the continuous development of therapeutics and vaccines to treat life-
threatening diseases. Drugs for treating of HIV represent most of the market, as 
8M new infections occur every year. We expect global infectious diseases 
revenue to reach $38.7bn by 2023 ($33.7bn in 2018). J&J has kept a share in the 
infectious diseases market of around 9.8%. We expect a slight decrease in J&J’s 
market share as its “other infectious diseases drugs” revenue keeps decreasing. 
By 2025 we expect the company’s market share to be around 9.4%. In 2026, with 
the expiration of PREZISTA
®
’s patent, we believe J&J’s market share to fall, 
reaching 7.4% by 2030. We forecast the company’s revenue to be: 
Infectious Diseases 2018A 2019E 2020F 2021F 2022F 2023F ... 2030F
Market size ($bn) 33.7$  34.6$  35.6$  36.6$  37.6$  38.7$  ... 47.0$  
J&J market share 9.8% 9.8% 9.7% 9.7% 9.6% 9.6% ... 7.4%
J&J revenue ($bn) 3.3$    3.4$    3.5$    3.6$    3.6$    3.7$    ... 3.5$     
Cardiovascular, metabolism and others: global annual revenue is expected to 
increase 4.8% each year until 2023 (reaching $41.3bn), after the U.S. 
government’s health insurer, Medicare, decided to increase spending in this 
division and as the expansion of new-generation anti-coagulants continues. 
J&J’s market share is expected to fall in 2019, to 15.1% (17.8% in 2018), 
following the success of Pfizer’s and Bristol-Myers Squibb’s drug, Eliquis. This 
drug competes directly with Xarelto
® 
and is clearly reducing its market share, as it 
is sold at a lower price. Eliquis’ sales have been growing ~20% per year. We 
expect Eliquis to continue gaining market share over Xarelto
®





market share to recover to 2018’s level of 2.7%, as a new 
extension
 
was approved in October 2019. Still, this should be partially offset by 
the expiration of Procrit
®
’s patent. Overall, we estimate J&J’s market share to 
have decreased to 13.1% by 2022. With the approval of Aprocitentan in 2022, we 
believe J&J will start to recover market share. Following that, we predict J&J’s 
market share will be 13.8% from 2026 onwards, and sales in this division to be: 
Exhibit 32. Worldwide cardiovascular 
and metabolism drugs revenue (2018 –
2023) 
Source: J&J Investor Presentation (May, 2019).  
Exhibit 31. Worldwide infectious 
diseases drugs market revenue (2018 – 
2023) 
Source: J&J Investor Presentation (May, 2019).  
 
 








Cardiac/Metabolism/Other 2018A 2019E 2020F 2021F 2022F 2023F ... 2030F
Market size ($bn) 32.6$  34.2$  35.8$  37.5$  39.4$  41.3$  ... 57.3$  
J&J market share 17.8% 15.1% 13.9% 13.4% 13.1% 13.2% ... 13.8%
J&J revenue ($bn) 5.8$    5.2$    5.0$    5.0$    5.2$    5.4$    ... 7.9$     
Medical Devices 
The medical devices industry is broad, ranging from large imagology devices to 
pacemakers and surgical instruments. Between 2014 and 2018, worldwide sales 
recorded a CAGR of ~2.1%, with revenue in 2018 exceeding $394.5bn. The U.S. 
market did not grow during the period, but is expected to grow ~2.8% in 2019.  
J&J is one of the industry’s main players, alongside Medtronic (U.S.), the largest 
in terms of sales, with market share of 7.7% in 2018; Koninklijke Philips NV (The 
Netherlands) with market share of 5.4%; Siemens Healthineers AG (Germany) 
with market share equal to 3.4% and Stryker (U.S.) also with 3.4%. These are 
J&J’s main competitors in the medical devices segment. J&J’s market share has 
fallen below 7% for the 1
st
 time since 2014, being 6.8% in 2018 and expected to 
be 6.5% in 2019. Yet, J&J still has the industry’s 2
nd
 largest market share.  
Most medical devices customers are healthcare systems such as Medicare 
(U.S.), who buy these appliances for patients and hospitals. Since healthcare 
insurers are almost only focused on lowering costs, sellers are forced to compete 
mostly based on prices. A study by The Commonwealth Fund in September, 
2017
3
, concluded that health insurers will increasingly have bargaining power to 
reduce prices. We believe that price decreases and increased shopping 
efficiency will not lower revenues, as demand increases should compensate 
lower prices. This should cause operating margins to fall. Yet, we expect this to 
be compensated following the firm’s restructuring program and the increase in 
the use of new production technologies such as 3D printing. However, investing 
in 3D printers will lead to higher capital expenditures.  
Ageing populations and the overall evolution of science will continue to drive up 
the medical devices market, as innovative products are developed. Moreover, 
according to the WHO, government health expenditure in developing countries 
per capita has doubled since the year 2000. However, companies from emerging 
economies have been claiming a larger share of the medical device industry. 
According to Statista, Chinese companies’ sales should grow at a CAGR of 
14.0% between 2013 and 2020. As for other emerging regions, revenue should 
grow at 9.9%. As for U.S. companies, revenue growth is expected to be 3.5%.  
Medical and surgical equipment: the U.S. market is expected to continue 
growing. According to Passport (Euromonitor), sales will grow 2.0% per year until 
                                                 
3
 Scheffler, Richard. 2017. Insurer Market Power Lowers Prices in Numerous Concentrated Provider Markets. The Commonwealth Fund 
Exhibit 33. Global medical devices 
revenue (2014 – 2019) 
Source: Passport (Euromonitor)  
Exhibit 34. Global medical devices 
market shares – Medtronic, Koninklijke 
Philips, Siemens Healthineers, Stryker, 
and J&J 
Exhibit 35. J&J gross profit margin 
Exhibit 36. Medical devices industry 
revenue (2013 – 2020) 
Source: Statista 
2013 2020 CAGR
U.S. 137$    174$    3.5%
Japan 41$      49$      2.6%
Germany 26$      29$      1.6%
China 22$      55$      14.0%
Other emerging 17$      33$      9.9%
Rest of the world 97$      130$    4.3%
Total 340$    470$    4.7%
 
 








2023, with total revenue reaching $104.7bn. After that, annual revenue should 
grow at 1.8%. In international markets, growth is expected to be superior, as 
healthcare spending and disposable income in emerging countries keeps 
increasing. Thus, sales should increase 5.6% YoY, reaching $308.5bn in 2023.  
J&J’s U.S. market share in this division has increased between 2014 and 2017, 
but fell to 6.7% in 2018 being expected to decrease further, to 6.0% in 2019. 
International market share decreased from 3.7% in 2017 to 3.6% in 2018 and 
3.3% (expected) in 2019. This is due to the discontinuation of diabetes care and 
due to poor performance in specialty surgery equipment. Yet, J&J’s products 
remain the best in treating and preventing strokes and the company is set to 
launch in the next 18 months a smart micro-catheter that will decrease the 
average surgery time in half. Also, J&J is investing in innovative solutions for 
gastric and thoracic surgery, which we believe will cause J&J to gain market 
share in the surgery division. All things considered, we trust that by 2023 J&J’s 
U.S. market share will be 6.4% and in international markets, 3.4%. From then on, 
we believe these will stay the same. Therefore, we estimate sales to be: 
Medical/Surgical Equipment 2018A 2019E 2020F 2021F 2022F 2023F ... 2030F
Market size ($bn) 329.5$ 334.9$ 354.1$ 372.5$ 392.3$ 413.2$ ... 570.3$ 
J&J market share 4.5% 4.1% 4.1% 4.2% 4.2% 4.2% ... 4.0%
J&J revenue ($bn) 14.8$   13.8$   14.6$   15.5$   16.4$   17.2$   ... 22.7$    
Orthopaedic devices: sales in the U.S. are estimated to grow 1.7% per year, 
according to Passport (Euromonitor). As such, revenue should reach $16.7bn by 
2023. Again, international markets are expected to increase at a faster pace 
(4.5%), reaching $37.9bn by 2023.  
In the U.S., J&J is the leading player, with market share consistently above 
32.6% since 2014. Still, J&J’s market share decreased in 2018 to 34.4% and is 
expected to decrease again in 2019, to 33.8%, due to poor sales of its spine-
related products. The company’s spine division will be underperforming until 
2021, as digital surgery at J&J is still not fully developed. Following the 
company’s partnerships with Brainlab, with China's #1 robotic surgery company 
and the acquisition Auris, by 2021 digital surgery should be fully operational. 
From then on, we believe J&J will recover some of its U.S. market share, 
increasing it from 33.6% in 2021 to 34.8% by 2026. In international markets all 
divisions have been performing worse, as players from emerging economies 
continue to gain market share. J&J’s market share reduced from 14.1% in 2014 
to 11.8% in 2018. In 2019, J&J’s share in international markets will decrease to 
11.6%. We expect further losses in market share until 2021, to 11.1%. Following 
the development of digital surgery in 2021, we believe J&J will be able to sustain 
its market share, from then onwards. As such, we forecast revenue as: 
Exhibit 37. Worldwide medical/surgical 
equipment revenue (2018 – 2023) 
Source: Passport (Euromonitor) 
Exhibit 38. Worldwide orthopaedic 
devices revenue (2018 – 2023) 
Source: Passport (Euromonitor) 
 
 








Orthopaedics 2018A 2019E 2020F 2021F 2022F 2023F ... 2030F
Market size ($bn) 45.8$   45.8$   48.2$   50.2$   52.4$   54.6$   ... 70.3$   
J&J market share 19.4% 19.2% 18.8% 18.4% 18.3% 18.2% ... 17.4%
J&J revenue ($bn) 8.9$     8.8$     9.0$     9.2$     9.6$     9.9$     ... 12.2$    
Contact lenses: global turnover is expected to grow at a similar pace in the U.S. 
and in international markets. According to Grand View Research, innovation will 
continue to drive up the market, together with rising disposable income levels and 
the tendency to wear contact lenses instead of glasses. As such, global revenue 
should grow 4.4% per year, until 2023. After that, we believe that growth in the 
U.S. will decrease to 4.1%, as the effect of the shift in preferences fades. 
Therefore, we expect U.S. revenue to be $8.7bn in 2023. In international 
markets, annual sales are estimated to reach $15.0bn by 2023.  
J&J’s U.S. market share has been increasing since 2016, from 15.7% to 17.6% in 
2018 and 2019. As for international markets, J&J’s market share is increasing 
since 2014, from 14.4% to 17.1% in 2018 and 2019. With the launch of Acuvue
®
 
Oasys (innovative contact lenses that adapt to light conditions), we expect J&J to 
keep increasing its global market share. Therefore, we believe J&J will have 
increased its U.S. market share to 18.9% and to 18.5% in international markets, 
by 2023. Thus, we believe revenue will evolve as follows:  
Contact Lenses 2018A 2019E 2020F 2021F 2022F 2023F ... 2030F
Market size ($bn) 19.1$   19.7$   20.7$   21.7$   22.7$   23.7$   ... 31.8$   
J&J market share 17.3% 17.3% 17.7% 18.1% 18.4% 18.7% ... 18.7%
J&J revenue ($bn) 3.3$     3.4$     3.7$     3.9$     4.2$     4.4$     ... 5.9$      
Consumer Goods 
All consumer goods’ industry considerations in this report only account for J&J’s 
divisions of the consumer goods segment – beauty and women care, baby care, 
OTC drugs, wound care and oral care. Since each division’s revenue drivers and 
trends are different, these were analysed separately, as follows: 
OTC Drugs & Wound Care: wound care includes bandages, tapes, patches and 
other products, while OTC medicines are drugs sold without the need for a 
prescription from a healthcare professional. Drivers of the demand for wound 
care include the growing need for faster wound recovery and increase in the 
number of surgeries. Estimates by Passport (Euromonitor) state that the U.S. 
market will grow less than international markets (at 0.7% per year), reaching 
$1.0bn in 2023. In the remaining countries, revenue is expected to grow at 3.9%, 
going from $2.4bn in 2018 to $2.8 in 2023. The market for OTC drugs should 
expand fast, mainly due to a growing number of patent expirations on 
prescription drugs that emerge as OTC. The U.S. market is projected to grow 
2.1% per year, from $26.8bn in 2018 to $29.8bn in 2023. As for international 
Source: Passport (Euromonitor) 
Exhibit 39. Worldwide contact lenses 
revenue (2018 – 2023) 
Exhibit 40. Worldwide OTC drugs & 
wound care revenue (2018 – 2023) 
Source: Passport (Euromonitor) 
 
 








markets, growth is projected to be 5.4%, with annual revenue reaching $107.4bn 
in 2023. 
J&J is a leading player in OTC and wound care, with market share of ~5.0% in 
2018. J&J’s main competitors are multinational pharmaceutical companies, such 
as Sanofi (market share of 6.3%), GlaxoSmithKline (4.8%), Bayer AG (4.5%) and 
Novartis (4.2%). J&J recorded the largest revenue in 2015 and 2016, but since 
then has been surpassed by Sanofi. J&J’s global market share has been 
decreasing because of international sales. In the U.S., the company’s market 





, with sales growing for the last 4 years. Following this, 
and the acquisition of Zarbee’s
TM
 in 2018, we believe J&J’s market share will 
keep increasing. J&J’s U.S. market share in 2019 is expected to rise to 7.3% 
(from 6.9%) and by 2023 it should be about 8.0%. Moreover, J&J’s share in 
international markets is expected to slightly decrease from 2.9% to 2.8%. After 
that, we expect the company’s share to continue decreasing as the impact of 
Zarbee’s
TM
 on revenue will happen mostly in the U.S. and as pharmaceutical 
companies from emerging markets continue to gain ground. We expect J&J’s 
international market share to reach 2.7% by 2023. We estimate OTC drugs and 
wound care revenue to be as follows: 
OTC Drugs & Wound Care 2018A 2019E 2020F 2021F 2022F 2023F ... 2030F
Market size ($bn) 116.4$ 117.9$ 123.7$ 129.0$ 134.8$ 141.1$ ... 201.7$ 
J&J market share 4.3% 4.3% 4.2% 4.2% 4.1% 4.1% ... 3.7%
J&J revenue ($bn) 5.0$    5.1$    5.2$    5.4$    5.5$    5.7$    ... 7.5$     
Baby Care: products include wipes, feeding accessories, disposable diapers, 
soaps, shampoos, body care products and others. It has been verified an 
increase in baby care products due to rising concerns on child and baby health 
protection. Even though global fertility rates have been decreasing for many 
years, being at all-time low levels, the above-mentioned concerns are expected 
to increase the global market for baby products. However, in the U.S. alone, low 
fertility rates are expected to dictate a shrinking market. Following Orbis’ 
estimates, we believe annual U.S. sales will decrease 0.3% per year, remaining 
at $6.1bn by 2023. On the other hand, global international sales are expected to 
rise 3.2% a year, reaching $37.0bn in 2023 (from 2018’s turnover of $31.1bn). 
The three main players are Johnson & Johnson (leader with market share equal 
to 5.0% in 2018), Kimberly-Clark (3.2%) and Procter & Gamble (2.1%). J&J’s 
market share has been decreasing since 2014 (from 7.6% in 2014 to 5.0% in 
2018). This is mainly due to J&J’s recent law suits regarding its baby powder 
products. It is clear that those litigations are causing reputational damage that is 
impacting J&J’s performance. However, the negative effect of law suits is 
Exhibit 41. Global OTC/wound care 
market share – Sanofi, Novartis, Bayer 
AG, GSK, J&J  
Exhibit 43. Global baby care market 
shares – P&G, Kimberly-Clark, J&J 
Exhibit 42. Worldwide baby care market 












happening mostly in the U.S.. In international markets, market share loss is 
mainly driven by the entrance of new players from emerging markets (such as 
Brazil’s Natura&Co who entered the baby care market in 2017, and in 2018 its 
global market share was ~1.6%). We expect that, companies from emerging 
economies continue to gain market share worldwide, since most growth expected 
for the baby care market growth will happen in those countries. Thus, we believe 
J&J’s U.S. market share will stabilize around 5.8% by 2021, as reputational 
damage dissipates, while in international markets it should keep decreasing. We 
expect J&J’s international market share to fall to 3.2% by 2023 and to 2.7% by 
2030, after which we expect it to stabilize. As such, we forecast sales to be: 
Baby Care 2018A 2019E 2020F 2021F 2022F 2023F ... 2030F
Market size ($bn) 37.4$  38.7$  39.9$  41.1$  42.2$  43.2$  ... 51.7$  
J&J market share 5.0% 4.3% 4.0% 3.8% 3.7% 3.6% ... 3.1%
J&J revenue ($bn) 1.9$    1.7$    1.6$    1.6$    1.6$    1.6$    ... 1.6$     
Beauty & Women Care: the industry is mostly dominated by large multinationals 
such as J&J itself (market share of 1.2% in 2018), L’Oréal Paris (leading 
company with market share of 7.2%), P&G (2.8%), Nivea (1.9%) and Chanel 
(undisclosed revenue). Global beauty products sales in 2018 were $441.9bn, 
meaning a CAGR of 0.6% since 2014. According to Passport (Euromonitor), U.S. 
revenue will grow 1.9% per year, while international markets will expand 6.6% 
per year, until 2023, mostly due to the increase in the average disposable income 
of populations and due to the effect of climate changes that are driving up the 
need for skin care products and sunscreens. Moreover, there has been a recent 
increase in the use of beauty and care products for men. As such, we believe 
that, after 2023, growth will stay the same, as the above-mentioned drivers 
should continue. U.S. should reach $89.1bn by 2023. As for international 
markets, we expect annual turnover to be $497.4bn in 2023. 
J&J’s market share has been the same for the last 5 years. Nivea has also kept 
its share during the period, while P&G has lost some market share (-0.3pps when 
compared to 2014), and L’Oréal Paris, has consolidated its position (+0.2pps 
than in 2014). J&J’s U.S. international market share has been increasing due to 
Dr.Ci:Labo’s success in Japan (most sold medical cosmetic skincare brand in 
Japan with ~40% of market share) and due to the success of the company’s anti-
ageing products. We expect J&J’s international market share to increase to 0.6%. 
In the U.S., we expect J&J’s market share to return to 3.0% by 2022 as the 
reputational damage of the company’s law suits in relation to asbestos findings in 
baby powder, dissipates. Overall, we estimate sales to be as follows: 
Exhibit 45. Global beauty & women care 
market shares – L’Oréal Paris, P&G 
Nivea, J&J 
Exhibit 44. Worldwide beauty & women 
care revenue (2018 – 2023) 
Source: Passport (Euromonitor) 
 
 








Beauty & Women Care 2018A 2019E 2020F 2021F 2022F 2023F ... 2030F
Market size ($bn) 441.9$ 459.7$ 489.1$ 518.4$ 550.9$ 586.6$ ... 880.0$ 
J&J market share 1.2% 1.2% 1.2% 1.2% 1.2% 1.2% ... 1.1%
J&J revenue ($bn) 5.4$    5.6$    5.8$    6.1$    6.5$    6.8$    ... 9.4$     
Oral Care: J&J’s oral care division relies on LISTERINE
®
, the world’s most sold 
mouthwash product. The leading players worldwide are P&G’s Oral-B brand and 
Colgate-Palmolive. However, even if these companies sell mouthwash elixirs that 
directly compete with LISTERINE
®
, their products focus mostly on toothpastes 
and toothbrushes. According to Passport (Euromonitor), revenue will grow 1.3% 
per year in the U.S., until 2023. In other markets, revenue is expected to fall 0.9% 
in 2019, but to grow afterwards, 3.2% per year as a result of growing concerns 
regarding oral hygiene. We believe that, afterwards, growth may continue the 
same. U.S. annual revenue should achieve $9.1bn by 2023, while international 
turnover should reach $42.5bn. 
LISTERINE
®
’s market share in the U.S. is expected to fall to 7.2% in 2019, after 
being above 7.3% for the past 5 years. We believe the brand might recover some 
share, to 7.4% from 2021 onwards. Expectation is that LISTERINE
®
 will remain 
as the #1 mouthwash product, due to its effectiveness and brand reputation. In 
international markets, LISTERINE® is also the leading brand. Yet, its market 
share has been decreasing every year, as private label products keep increasing 
their share of the market. Still, in 2019, expectation is that market share will be 
the same as in 2018 – 2.4%. We believe that, after having experienced a 
decrease in market share, J&J will be able to sustain its share of 2.4% in 
international markets, retaining its position as the world’s most sold oral care 
brand. We forecast J&J’s oral care revenue to be as follows: 
Oral Care 2018A 2019E 2020F 2021F 2022F 2023F ... 2030F
Market size ($bn) 46.4$  46.2$  47.5$  48.9$  50.2$  51.6$  ... 62.8$  
J&J market share 3.3% 3.3% 3.3% 3.3% 3.3% 3.3% ... 3.2%
J&J revenue ($bn) 1.6$    1.5$    1.6$    1.6$    1.7$    1.7$    ... 2.0$     
Intrinsic Valuation 
Our fundamental valuation was performed by estimating the firm’s cash flows 
until 2030. By then, we expect J&J to have achieved a mature state in which the 
return on invested capital (ROIC) and growth are very stable. The DCF model 
resulted in a share price of $166.00, defined as our target price and meaning that 
J&J is trading at a discount. We decided to compute a sum-of-the-parts (SOTP) 
DCF model, to assess if the sum of J&J’s segments, valued individually, was 
different from J&J’s value as a whole. The outcome of the SOTP DCF model was 
very close to that of the DCF, a price of $164.07 per share. From this, we could 
conclude that there is no conglomerate premium or discount. 
Exhibit 46. Worldwide oral care market 
revenue (2018 – 2023) 
Source: Passport (Euromonitor) 
 
 








 Model Description 
In addition to J&J’s three operating segments, a 4
th
 one was added, that regards 
centralized matters of operations which cannot be allocated to any particular 
segment (general corporate).  
 Revenue 
Following the estimation of revenues for all of J&J’s division within each segment, 
presented in the Industry Overview section, we believe J&J’s revenue from core 
operations will evolve as such:  
Revenues Forecast 2018A 2019E 2020F 2021F 2022F 2023F ... 2030F
Pharmaceutical
Market size ($bn) 1 500$ 1 539$ 1 637$ 1 731$ 1 834$ 1 941$ ... 2 839$ 
J&J market share 2.7% 2.8% 2.7% 2.7% 2.7% 2.6% ... 2.5%
J&J revenue ($bn) 40.7$   42.8$   44.2$   46.1$   48.8$   51.3$   ... 72.3$   
Medical Devices
Market size ($bn) 394$    400$    423$    444$    467$    492$    ... 672$    
J&J market share 6.8% 6.5% 6.4% 6.4% 6.4% 6.4% ... 6.1%
J&J revenue ($bn) 27.0$   26.0$   27.3$   28.6$   30.1$   31.6$   ... 40.9$   
Consumer Goods
Market size ($bn) 642$    663$    700$    737$    778$    823$    ... 1 196$ 
J&J market share 2.2% 2.1% 2.0% 2.0% 2.0% 1.9% ... 1.7%
J&J revenue ($bn) 13.9$   13.9$   14.2$   14.7$   15.2$   15.8$   ... 20.5$   
Total Revenue 81.6$   82.6$   85.7$   89.4$   94.1$   98.6$   ... 133.7$  
 Operating Costs 
Pharmaceutical: gross profit margin is expected to be 16.8% in 2019. We 
expect this margin to get lower as a result of stricter U.S. drug price regulation 
and patent losses that drive prices down. We estimate gross profit margin of U.S. 
operations to have decreased 1.1pps by 2023 and 3.6pps by 2030. In addition, 
we believe a patent loss will decrease the drug’s gross profit margin in 5.4pps, 
four years after expiration. We expect that four years after patent expiration, all 
new entrants to be successfully producing the drug. Therefore, we forecast J&J’s 
pharmaceutical gross profit margins and COGS to evolve as follows: 
Pharmaceutical 2018A 2019E 2020F 2021F 2022F 2023F ... 2030F
Revenues ($bn) 40.7$  42.8$  44.2$  46.1$  48.8$  51.3$  ... 72.3$  
Gross Profit Margin 84.5% 83.2% 83.0% 82.9% 82.6% 82.5% ... 81.2%
COGS ($bn) -13.2 $ -12.4 $ -13.1 $ -13.7 $ -14.5 $ -15.2 $ ... -19.7 $  
Regarding R&D, in the 3
rd
 quarter earnings report, J&J’s management stated that 
investment in R&D would increase in the next years, to ensure the continuous 
discovery of innovative solutions. As such, we expect R&D expenses to continue 
growing faster than revenues, on average, 7.2% per year until 2023. After that, 
we predict them to grow at the same pace as revenues. Since we do not expect 
any restructuring program in this segment, we assume no future charges. D&A 
Exhibit 49. Pharmaceutical segment 
R&D expenses forecast ($bn) 
Exhibit 47. Revenue breakdown by 
segment (2018 – 2023) 















expenses were forecasted based on PP&E and intangible assets, while SM&A 
expenses were estimated as a constant % of revenues (21.8%). The same 
rationale was used for the remaining segments. Therefore, we expect J&J’s 
pharmaceutical operating results to be as follows: 
dollars in billions 2018A 2019E 2020F 2021F 2022F 2023F ... 2030F
Gross Profit 34.4$  35.6$  36.7$  38.2$  40.3$  42.3$  ... 58.7$  
EBITDA 17.3$  16.8$  17.0$  17.5$  18.2$  18.8$  ... 25.7$  
EBIT 13.5$  13.0$  13.0$  13.2$  13.7$  14.0$  ... 19.3$   
Medical devices: in 2015 Johnson & Johnson started a restructuring program to 
eliminate 4% to 6% of its MD workforce and increase the availability of resources 
to invest in new and innovative solutions. The program finished in 2018 with total 
restructuring costs reaching $2.5 bn. The program led to pre-tax annual savings 
of $0.7 bn in 2018, expected to be 0.8bn to $1bn from 2019 onwards. We believe 
that operating margins will not decrease after 2019, following health insurers’ 
pressure for lower prices, since J&J (and its MD competitors) are investing in 3D 
printers to maximize production efficiency. As such, we estimate COGS as: 
Medical Devices 2018A 2019E 2020F 2021F 2022F 2023F ... 2030F
Revenues ($bn) 27.0$  26.0$  27.3$  28.6$  30.1$  31.6$  ... 40.9$  
Gross Profit Margin 51.0% 52.2% 52.1% 52.1% 52.0% 52.0% ... 51.8%
COGS ($bn) -13.2 $ -12.4 $ -13.1 $ -13.7 $ -14.5 $ -15.2 $ ... -19.7 $  
In the medical devices segment, J&J’s management also expects to increase its 
levels of R&D charges, growing on average 5.7% per year, until 2023. Moreover, 
we do not expect any relevant impairments or restructuring charges.  All things 
considered, we forecast J&J’s medical device results to be as such: 
dollars in billions 2018A 2019E 2020F 2021F 2022F 2023F ... 2030F
Gross Profit 13.8$  13.6$  14.2$  14.9$  15.7$  16.4$  ... 21.2$  
EBITDA 6.8$    6.2$    6.4$    6.7$    6.9$    7.2$    ... 9.2$    
EBIT 4.7$    4.1$    4.2$    4.3$    4.5$    4.6$    ... 5.7$     
Consumer goods: the gross profit margin has been decreasing since 2016, 
when it was 49.7%. In 2019, we expect it to be the same as in 2018, 45.5%. In 
the 3
rd
 quarter earnings release, J&J’s management stated that margins would 
start improving in the coming year, following increases in competitiveness of the 
products’ portfolio. As such, we believe the gross profit margin will gradually 
increase, reaching 48.8% by 2023, and COGS to be as follows: 
Consumer Goods 2018A 2019E 2020F 2021F 2022F 2023F ... 2030F
Revenues ($bn) 13.9$  13.9$  14.2$  14.7$  15.2$  15.8$  ... 20.5$  
Gross Profit Margin 45.5% 45.5% 46.4% 47.2% 48.0% 48.8% ... 48.8%
COGS ($bn) -7.5 $   -7.6 $   -7.6 $   -7.8 $   -7.9 $   -8.1 $   ... -10.5 $  
We forecast R&D charges to be 4.3% of revenues and do any restructuring 
charges. Thus, we estimate J&J’s consumer goods future operating results to be: 
Exhibit 50. Medical devices segment 
R&D expenses forecast ($bn) 
Exhibit 51. Consumer goods segment 
R&D expenses forecast ($M) 
 
 








dollars in billions 2018A 2019E 2020F 2021F 2022F 2023F ... 2030F
Gross Profit 6.3$    6.3$    6.6$    6.9$    7.3$    7.7$    ... 10.0$  
EBITDA 3.2$    2.7$    2.9$    3.1$    3.3$    3.6$    ... 4.6$    
EBIT 2.5$    2.0$    2.2$    2.4$    2.5$    2.8$    ... 3.5$     
General corporate: in 2018 the company announced a restructuring of its global 
supply chain to enable the focus on critical processes and technologies. The 
company expects to generate annual pre-tax savings of $0.6bn to $0.8bn, while 
total restructuring costs should remain below $2.3 bn. This segment includes the 
above-mentioned restructuring expenses and the savings that arise from this 
program, together with SM&A and D&A expenses that are not allocated to any of 
the remaining operating segments. Moreover, we considered operating cash 
taxes in accordance with Mckinsey & Company’s Valuation (2015)
4
. 
Overall, we forecast J&J’s consolidated results from core operations to be:  
dollars in billions 2018A 2019E 2020F 2021F 2022F 2023F ... 2030F
Revenues 81.6$  82.6$  85.7$  89.4$  94.1$  98.6$  ... 133.7$ 
Gross Profit 54.5$  55.6$  57.8$  60.5$  64.0$  67.2$  ... 90.7$   
Gross Profit margin 66.8% 67.2% 67.4% 67.7% 67.9% 68.2% ... 67.9%
EBITDA 26.7$  25.1$  26.0$  27.1$  28.5$  29.9$  ... 39.7$   
EBITDA margin 32.8% 30.4% 30.3% 30.3% 30.3% 30.3% ... 29.7%
EBIT 19.8$  18.3$  18.7$  19.4$  20.3$  21.2$  ... 28.0$   
EBIT margin 24.3% 22.1% 21.8% 21.7% 21.6% 21.5% ... 20.9%
NOPLAT 14.0$  15.5$  16.5$  17.1$  18.0$  18.8$  ... 24.8$   
growth YoY 10.9% 6.3% 3.8% 4.9% 4.3% ... 3.8%  
 Net Working Capital & Capital Expenditures 
To forecast inventories, accounts payable and accounts receivable, we analysed 
the evolution of the average holding period, collection period and payable period, 
respectively, with 2018’s value being assumed from 2019 onwards. Operating 
cash was assumed to be 3.1% of revenues, the average of previous years. The 
remaining captions were forecasted based on revenues, purchases or SM&A 
expenses. As J&J does not disclose information on production capacity, we 
forecasted PP&E as a % of revenues. As we expect J&J to keep investing in 3D 
printers to maximize production efficiency in the MD segment, we expect PP&E 
in proportion to sales to have increased to 23.6% by 2023, following larger 
CAPEX in the next few years. Intangible assets will change as patents are 
approved and expire, so they were forecasted based on revenue, as revenue 
drivers account for patent additions and losses. The table below summarizes our 
forecast for NWC, PP&E and intangible assets: 
                                                 
4
 Koller, Tim, Goedhart, Marc and David Wessels. 2015. Valuation “Measuring and managing the value of companies”. New Jersey: John 
Wiley & Sons, Inc. and Hoboken. 
Exhibit 53. Average inventory holding 
period 
Inventory 2015 2016 2017 2018
# days 138 136 121 117
Exhibit 54. Average collection period  
Receivables 2015 2016 2017 2018
# days 57 57 60 62
Exhibit 55. Average payable period  
Payables 2015 2016 2017 2018
# days 113 116 119 104
Exhibit 52. General corporate D&A and 
SM&A expenses forecast ($M) 
 
 








dollars in billions 2018A 2019E 2020F 2021F 2022F 2023F ... 2030F
NWC 2.7$    -1.1 $   3.6$    3.7$    3.8$    4.0$    ... 5.5$     
∆ NWC -1.4 $   -3.8 $   4.7$    0.0$    0.1$    0.2$    ... 0.2$     
PP&E + intangible assets 64.6$  64.9$  68.6$  72.2$  76.7$  81.1$  ... 109.9$ 
CAPEX 1.3$    7.1$    11.0$  11.3$  12.7$  13.1$  ... 13.4$    
 Target D/E Ratio 
In 2017 J&J’s D/E ratio was 31.3%, while in 2018 it was 22.5%. As for its peers, 
the median D/E ratio is 34.9%. We believe that the average D/E ratio between 
2017 and 2018 is a fair assumption for J&J’s target capital structure, being also 
similar to its peers’ capital structure. Therefore, we assume a target D/E ratio of 
27% from 2019 onwards. After determining J&J’s debt repayment schedule, and 
in order to maintain the target D/E ratio, we assume the company will keep 
issuing debt. Having defined the target D/E ratio (in book values), we were able 
to compute the D/E ratio to use in our WACC computations (in market values), 
using J&J’s book-to-market ratios. As such, J&J’s target D/E in market values is 
4.5%.  
 Discount Rates 
CAPM estimations were based on a MRP of 5.96% retrieved from Damodaran’s 
MRP database, updated on January 2019
5
. The 10-year U.S. treasury yield was 
used as the risk-free rate, as J&J is a U.S. based company (1.92%). 
Cost of debt: to estimate the cost of debt we used two different approaches. The 
first was to estimate the weighted-average yield-to-maturity from the company’s 
outstanding debt and subtract J&J’s probability of default * LGD. The default 
probability was retrieved from Bloomberg (0.0001%). As for the LGD, we used a 
standardized value for large cap firms: 53.90%. The weights for the YTM were 
computed using the market value of outstanding debt. The result was a cost of 
debt equal to 2.00%. The second approach was to retrieve the credit spread that 
should be applied to J&J’s debt, given that its AAA rating: 0.75%.  Afterwards, we 
applied the spread to the current risk-free rate (1.92%) and reached cost of debt 
for J&J equal to 2.67%. Even if the first approach is the most accurate approach 
for determining J&J’s cost of debt, we believe that a r
D
 of 2.0% might be too low 
to use in perpetuity, as it might be driven down by the low current interest rate 
environment. For instance, some of J&J’s European peers have current costs of 
debt that are clearly not to be sustained in perpetuity (Novo-Nordisk’s r
D
 = -0.18% 
and Sanofi’s r
D
 = 0.02%). Therefore, we decided to use the average between the 
two approaches: r
D
 equal to 2.33%, which implies a β
D
 of 0.07. This cost of debt 
                                                 
5
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Exhibit 56. Target D/E ratio 










Cost of Debt 2.00%
U.S. 10-y Treasury yield 1.92%
AAA Credit Spread 0.75%
Cost of Debt 2.67%
Average Cost of Debt 2.33%
YTM - LGD*P(D) Approach
YTM - LGD*P(D) Approach
 
 








was used in the WACC estimation and is assumed to be the interest rate for all 
debt issues happening from 2019 onwards. 





), we retrieved from Bloomberg J&J’s and its peers’ levered equity β.  
Peers were selected based on the similarity of operations and market size. 
Afterwards, we unlevered the βs, to remove the effect of leverage and reflect only 
the operational risk. The remaining companies included in the peer group were: 
Novartis; Roche; Merck & Co.; Sanofi; Pfizer; Novo Nordisk; P&G and Medtronic. 
We assumed the peer group’s median unlevered β of 0.75 as J&J’s unlevered 
beta and, therefore, we estimate J&J’s r
U
 to be 6.37%. Then, with J&J’s D/E ratio 
of 4.5% and β
D
 = 0.07, we determined the company’s β
E
 of 0.78 and r
E
 of 6.55%. 
Finally, we estimated a WACC of 6.35%. 





 equal to 6.22%. The upper and lower values (95% confidence) for the 
r
E
 are 6.92% and 5.53%, respectively, which were used in the sensitivity analysis. 
 DCF Valuation 
Having assessed J&J’s WACC and FCFs until 2030, the only thing missing to 
compute the EV was the terminal growth. For the terminal growth we assumed 
the average growth rate between 2029 and 2030, using growth = ROIC * 
Reinvestment rate, as we believe that RONIC is at times, too dependent on 
patent approvals and expirations, being less stable through time. Moreover, 
between 2027 and 2030, growth ranges between 3.23% and 3.29%, being very 
stabilized. Thus, we computed J&J’s terminal value with growth = 3.26%. This 
derives from ROIC = 17.16% and RR = 18.97%. The weighted-average inflation 
rate expected for J&J in 2030 is 2.88%. We believe that, in perpetuity, J&J’s 
growth will be at least 2.88%, as revenue and FCFs should grow at least at the 
same rate of inflation. As such, we consider 3.26% to be a fair assumption for 
J&J’s terminal growth. In addition, we believe that a terminal ROIC considerably 
above the company’s WACC may be reasonable in this case, as J&J is a mature 
company, with ROIC consistently around 20%. We believe J&J’s capacity to 
develop innovative solutions, as a result of its rich resources and large R&D 
investment will continue in the future. 
Finally, we reached an Enterprise Value of $494.5bn. Our EQ-EV bridge included 
the value of financial (net) debt ($25.6bn), the value of non-core operations 
($25.8bn), the value of in-the-money stock options ($3.2bn) and J&J’s litigation 
charge expected for 2019 ($2.5bn). Total bridge value is $57.1bn, as there are no 
Exhibit 58. J&J’s peer group unlevered β 
Johnson & Johnson 0.70
Novartis 1.01
Roche Holding 1.05




Procter & Gamble 0.55
Medtronic 0.75
Median Unlevered β 0.75
Exhibit 60. J&J historical ROIC 







Cost of debt 2.33%
Tax rate 21.00%












minority interests or associates. Therefore, we reached a market value of equity 
equal to $437.4bn and share price of $166.00. 
 SOTP DCF 
For our SOTP approach we computed a WACC for each segment. Given J&J’s 
operating segments, peer groups of the most comparable companies were set 
solely with pure players from each segment. Besides being pure players, peers 
were also selected according to similarity of product portfolios and market cap. 
The result was an unlevered β of 0.85 for the pharmaceutical segment, 0.77 for 
the MD and 0.55 for the consumer goods segment. Using J&J’s capital structure, 
we estimate a r
E
 of 7.17% for the pharmaceutical segment, 6.72% for the MD 
segment and 5.35% for the consumer goods segment. Finally, the WACC for 
each segment was computed: 6.94% (pharmaceutical), 6.50% (MD) and 5.20% 
(consumer goods). Since there is no allocation of NWC and CAPEX per 
segment, all investment cash flows were discounted at the weighted-average 
WACC (6.65%) based on the weight of each segment’s CF from operations, 
together with general corporate expenses.  
Using the previously mentioned terminal growth rate of 3.26%, we reach an EV 
equal to $489.4, Equity value of $438.0 and share price of $164.07.  
Relative Valuation 
Our multiples valuation was performed using EV/EBITDA, through a SOTP 
approach, as we believe comparable companies for each segment provide a 
more accurate way to relatively evaluate J&J. Our relative valuation emerges as 
an attempt to corroborate our price target and to see whether investors might be 
wrongly positioning J&J. Therefore, the previously mentioned peer groups were 
used (excluding Estee Lauder and Pfizer, which were clear outliers). 
Peers’ multiples were obtained by going from Bloomberg’s market caps to the 
respective Enterprise Values, by summing up net debt and the remaining bridge 
value, which were derived from the financial reports. EVs were then divided by 
the 2019E adjusted EBITDA, sourced on broker consensus.  
Considering an interval ranging from the 1
st 
quartile to the 3
rd
 quartile for each 
group multiples, we got the respective ranges for each segment’s EVs and J&J’s 
implicit EV, using each segment’s 2020F adjusted EBITDAs – Pharma ($17.6bn), 
MD ($6.4bn) and consumer ($2.9bn). After subtracting J&J’s total bridge we 
reached J&J’s implicit market cap. Finally, by dividing it by the number of 
outstanding shares, we got a share price ranging between $145 and $175. 
Pharmaceutical Peers
Novartis Ag-Reg 1.00
Merck & Co. Inc. 0.69
Pfizer Inc 0.73
Abbvie Inc 0.93
Bristol-Myers Squibb Co 0.85
Novo Nordisk A/S-B 1.02
Astrazeneca Plc 0.68
Median Unlevered β 0.85
Medical Devices Peers
Medtronic 0.75
Siemens Healthineers AG 0.42
Stryker 0.80
Koninklijke Philips NV 0.95





Estee Lauder Cos 0.77
Median Unlevered β 0.55




Merck & Co. Inc. 16.2x
Bristol-Myers Squibb Co 19.9x




Siemens Healthineers AG 19.2x
Stryker 22.5x





Exhibit 62. Peers’ trading multiples 
 
 








Focusing on the median price ($159) and comparing it with J&J’s current price, 
we can conclude that, as shown by our DCF, the stock is trading at a discount. 
Range 1st Quartile Average Median 3rd Quartile
Pharma 17.6x 18.6x 18.3x 19.9x
MD 16.9x 18.6x 18.4x 20.0x
Consumer 14.7x 16.3x 15.7x 17.6x
Range 1st Quartile Average Median 3rd Quartile
Pharma 306 375$        324 428$   319 065$    346 861$      
MD 108 402$        118 859$   117 782$    128 239$      
Consumer 42'243$          46'856$     45'076$       50'579$         
Range 1st Quartile Average Median 3rd Quartile
EV 457 019$        490 143$   481 923$    525 679$      
Market Cap 399 928$        433 051$   424 832$    468 588$      






The following sensitivity analysis estimates how sensitive the price target is to our 
terminal growth assumption and how a different correlation between J&J and the 
S&P500, which impacts the stock’s β can affect our price target.  
Our terminal value weights 76% on the total enterprise value. We consider the 
worst case scenario for the growth rate, to be the weighted-average inflation rate, 
between the U.S. and the world - 2.88%. For the upside case, we assume the 
growth rate of our last forecasted years, through RONIC - 3.76%. Ceteris 
paribus, our target price would range from $150 to $195. 
From J&J’s regression on the S&P500 we built a range for the WACC, using a 
95% confidence interval for the β. The upper value leads to a WACC of 6.91%, 
while the lower value leads to WACC = 5.51%. Ceteris paribus, our DCF target 
price would be $137 with the largest WACC and $236 with the lowest. 
Considering both assumptions to vary along the above-mentioned ranges, our 
price would range from $125 (worst case scenario) to $296 (best case scenario). 
Scenario Analysis 
In addition to measuring how sensitive our target share price is to variations in 
the terminal growth and cost of capital, we decided to analyse how changes in 
J&J’s operating outcomes impact the share price. For that, we defined three 
scenarios regarding critical aspects of J&J’s operations: the success of J&J’s 
nearly-approved drugs and U.S. drug prices regulation. The scenarios were 
defined are as follows: Upside - nearly-approved drugs are approved and 
perform better than expected; price regulation does not take place and operating 
margins do not fall; Base Case - nearly-approved drugs are approved and 
Scenarios Growth Rate Price Target
Worst 2.88%  150$           
Base 3.26%  166$          
Best 3.76%  195$           
Scenarios Growth Rate Price Target
Worst 6.91%  137$          
Base 6.34%  166$          
Best 5.51%  195$          
Scenarios inflation rate DCF RONIC
Lower Beta  205$            232$    296$      
DCF  150$            166$    195$      
Upper Beta  126$            137$    156$      
 
 








perform as expected; price regulation reduces drug prices by 17.5%, on average, 
until 2030 (disregarding inflation); Downside - nearly-approved drugs do not get 
approved and price regulation levels U.S. drug prices with European prices. 
The table below summarizes the target price for each scenario, valued through 
our DCF model and the expected return in 12 months, accounting for dividends: 
Last Price: $145.87 Approvals Success Price Regulation Target Price 12m Return
Upside 125% 0.0% 176.75$       24%
Base Case 100% 17.5% 166.00$       17%
Downside 0% 35.0% 146.89$       3%  
Even with very strict price regulation and new patents not being approved, we 
believe J&J is worth more than its current price. We trust that an upside scenario 
is much more likely to happen than a downside: in addition to nearly-approved 
drugs not getting approved being an unlikely outcome, we think that in 10 years 
U.S. drug prices will still be different from European prices. It is important to note 
that J&J has been conducting a stock repurchase program, which signals that 
management believes the company is trading below its fair value. This reinforces 
our idea that J&J is being underpriced by the market. 
Investment Risks 
Main operating uncertainty lies on the settlement of the opioid dispute and in 
future law suits, as these lead to reputational damage and litigation charges. 
Moreover, our DCF model heavily relies on our WACC and growth assumptions. 
As seen, a higher WACC, together with a terminal growth rate equal to inflation, 
leads to a share price of $125. Still, we believe J&J will rise above inflation as a 
result of continuous innovation and advantages that come from J&J’s large R&D 
investments, and that our WACC assumptions are reasonable. 
Macroeconomic risks relate to changes in interest rates and in the state of the 
economy and stock market. The U.S. stock market has been bullish for a long 
time, with all U.S. indexes reaching record highs in 2019. A stock market crash is 
an ever-growing concern, mostly due to signs of an inverted yield curve, of an 
economic slowdown and due to a contracting U.S. manufacturing industry. 
Moreover, policies increasing interest rates could drive down J&J’s value, as its 














Income Statement - amounts in million $
Core Business 2018 2019E 2020F 2021F 2022F 2023F
Revenues 81 581$            82 646$            85 736$            89 409$            94 129$            98 626$            
COGS -27 091 $           -27 089 $           -27 958 $           -28 910 $           -30 170 $           -31 390 $           
Gross Profit 54 490$            55 557$            57 778$            60 499$            63 959$            67 236$            
SM&A expense -15 611 $           -18 480 $           -19 171 $           -19 993 $           -21 048 $           -22 054 $           
R&D expense -10 775 $           -11 420 $           -12 093 $           -12 890 $           -13 922 $           -14 945 $           
Impairment and restructuring charges -1 377 $            - 509 $              - 509 $              - 509 $              - 509 $              - 375 $              
EBITDA 26 727$            25 147$            26 005$            27 107$            28 480$            29 862$            
D&A expense -6 929 $            -6 889 $            -7 291 $            -7 684 $            -8 175 $            -8 655 $            
EBIT 19 798$            18 258$            18 714$            19 423$            20 305$            21 207$            
Operating Cash Taxes -5 791 $            -2 719 $            -2 193 $            -2 275 $            -2 316 $            -2 440 $            
NOPLAT 14 007$            15 539$            16 520$            17 148$            17 989$            18 767$            
Non -Core Business
Other income (expense), net -1 405 $            -2 500 $            - 590 $              - 590 $              - 590 $              - 337 $              
Interest Income  611$                583$                602$                622$                649$                676$               
Total Income (expense) - 794 $              -1 917 $             12$                 32$                 59$                 339$               
Non-Operating Income Taxes  436$                445$               - 3 $                  - 7 $                  - 14 $                - 79 $                
Total Other Comprehensive Income (Loss) -1 791 $            -1 684 $            -1 684 $            -1 684 $            -1 684 $            -1 684 $            
Net Non-operating Income -2 149 $            -3 156 $            -1 675 $            -1 660 $            -1 639 $            -1 424 $            
Financing
Interest expense, net of portion capitalized -1 005 $            - 949 $              -1 038 $            -1 086 $            -1 125 $            -1 196 $            
Tax shield  233$                220$                241$                252$                261$                277$               
Net Financing Result - 351 $              - 363 $              - 463 $              - 595 $              - 772 $              - 729 $               
Balance Sheet - amounts in million $
Core Business 2018 2019E 2020F 2021F 2022F 2023F
Operating Cash 2 619$             2 667$             2 683$             2 798$             2 946$             3 087$             
Inventories 8 599$             9 173$             8 960$             9 265$             9 669$             10 060$            
Accounts Receivable, net 14 098$            14 801$            14 497$            15 118$            15 916$            16 676$            
Prepaid expenses and other receivables 2 699$             2 220$             3 558$             3 746$             3 921$             4 075$             
Total current assets 28 015$            28 861$            29 697$            30 927$            32 451$            33 898$            
PP&E, net of accumulated depreciation 17 035$            17 048$            18 546$            20 011$            21 773$            23 553$            
Intangible assets, net 47 611$            47 846$            50 036$            52 179$            54 934$            57 558$            
Goodwill 30 453$            33 291$            33 291$            33 291$            33 291$            33 291$            
Total non-current assets 95 099$            98 185$            101 872$          105 481$          109 998$          114 402$          
Total operating Assets 123 114$          127 046$          131 570$          136 408$          142 449$          148 300$          
Accounts payable 7 537$             7 491$             7 903$             8 322$             8 709$             9 053$             
Accrued liabilities 7 601$             9 004$             9 077$             9 466$             9 965$             10 441$            
Accrued rebates, returns and promotions 9 380$             10 977$            7 761$             8 093$             8 520$             8 928$             
Total current liabilities 25 336$            29 977$            26 081$            27 273$            28 650$            29 942$            
Total operating liabilities 25 336$            29 977$            26 081$            27 273$            28 650$            29 942$            
Net core business 97 778$            97 069$            105 488$          109 135$          113 799$          118 359$          
Non-Core Business
Total non-operating assets 5 132$             5 501$             4 982$             5 195$             5 470$             5 731$             
Total non-operating liabilities 29 880$            31 590$            30 768$            30 433$            30 234$            29 297$            
Net non-core -24 748 $           -26 089 $           -25 786 $           -25 238 $           -24 765 $           -23 566 $           
Financing and Shareholders Equity
Excess Cash -15 488 $           -13 582 $           -14 090 $           -14 693 $           -15 469 $           -16 208 $           
Marketable securities -1 580 $            -1 696 $            -1 759 $            -1 835 $            -1 932 $            -2 024 $            
Loans and notes payable 2 796$             1 660$             1 612$             1 612$             1 478$             1 478$             
Long-term debt 27 684$            26 184$            25 134$            23 338$            21 338$            19 785$            
Debt Issued -$                 6 520$             10 534$            14 137$            18 525$            22 458$            
Total Financial Liabilities 13 412$            19 086$            21 431$            22 559$            23 940$            25 489$            
Total Shareholders' equity 59 618$            51 894$            58 271$            61 338$            65 094$            69 304$             
Cash Flows Map - amounts in million $
Core Business 2018 2019E 2020F 2021F 2022F 2023F
EBIT 19 798$            18 258$            18 714$            19 423$            20 305$            21 207$            
Operating cash taxes -5 791 $            -2 719 $            -2 193 $            -2 275 $            -2 316 $            -2 440 $            
Noplat 14 007$            15 539$            16 520$            17 148$            17 989$            18 767$            
D&A 6 929$             6 889$             7 291$             7 684$             8 175$             8 655$             
OCF 20 936$            22 428$            23 811$            24 833$            26 164$            27 422$            
Net CAPEX -1 342 $            -7 137 $            -10 978 $           -11 293 $           -12 692 $           -13 060 $           
∆ NWC -1 364 $            -3 795 $            4 732$             39$                  147$                155$                
Goodwill 30 453$            33 291$            33 291$            33 291$            33 291$            33 291$            
∆ Other Operating Assets 1 453$             -2 838 $            -$                 -$                 -$                 -$                 
Operating FCF 22 411$            16 248$            8 101$             13 501$            13 325$            14 207$            
Non-Core Business
Net Non-operating income -2 149 $            -3 156 $            -1 675 $            -1 660 $            -1 639 $            -1 424 $            
∆ Non-operating Assets, net -797 $               1 341$             -303 $               -548 $               -473 $               -1 199 $            
Non-operating FCF -2 946 $            -1 815 $            -1 978 $            -2 208 $            -2 112 $            -2 623 $            
Total FCF 19 465$            14 432$            6 123$             11 293$            11 213$            11 584$            
Financing activities
Tax Shield 233$                220$                241$                252$                261$                277$                
Interest expense, net -1 005 $            -949 $               -1 038 $            -1 086 $            -1 125 $            -1 196 $            
∆ Net Debt -5 802 $            5 674$             2 345$             1 128$             1 381$             1 548$             
Equity CF -12 891 $           -19 377 $           -7 671 $            -11 587 $           -11 730 $           -12 214 $           
Financial FCF -19 698 $           -14 652 $           -6 364 $            -11 545 $           -11 474 $           -11 861 $            
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Interest rates play a significant role in the determination of Johnson & Johnson’s fundamental 
value through the DCF approach. This analysis estimates how different treasury yields, 
namely due to changes in interest rate policies and investors’ expectations, may impact J&J’s 
WACC and target price. For that, three scenarios were defined based on historical values for 
the U.S. 10-year treasury yields. The study allowed for the conclusion that even small 
changes in treasury yields can lead to very different target prices. Assuming equal 
probabilities of yields going up/down, J&J’s target price would be $165.27, reinforcing that 
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Interest rate policies and treasury yields 
Central banks around the world, and the U.S.’s Federal Reserve (Fed), are responsible for 
setting monetary policies, which includes setting interest rates. In the U.S., the Federal Open 
Market Committee (FOMC) determines the federal funds rate – interest rate charged between 
banks on an overnight basis and the rate at which banks deposit money in the central bank. 
These rates serve as a target rate for all other interest rates, especially for loans and bonds 
with short maturities and for the most creditworthy corporate clients.  
Monetary policy and changes in interest rates are many times used to stimulate the economy 
in order to avoid economic downturns or to recover from a recession. Yet, it can also be used 
to prevent rapid increases in inflation and overly strong economic expansions. In an attempt 
to stimulate the economy after the 2008 financial crisis, many central banks around the world, 
and the Fed, lowered interest rates. Low interest rates drive up the demand for loans, as these 
become cheaper, so people and businesses tend to increase their levels of leverage. In 
addition, people have fewer incentives to save, since returns on deposits are low. With more 
to spend, and less incentives to save, people tend to consume more goods and services. As 
spending increases, companies record more revenue and should generate larger cash flows, 
which drives up the value of businesses and stock prices. From an investor’s perspective, low 
interest rates mean lower returns on bond investments. As such, in a low interest rate 
environment, investors focus on equities, as their opportunity cost of investing in a safer asset 
(namely in the risk-free asset), is lower. Our decision was to consider the U.S. 10-year 
treasury yield as the risk-free rate.  
U.S. treasury securities are initially sold at an auction held by the Treasury Department. After 
the auction, treasury yields continuously change every day, as most investors resell them on 
the secondary market. Treasury yields go down when investors increase their desire for 
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bonds, over riskier investments such as stocks, or when they expect interest rates to go down 
in the future and want to lock in on current rates. Contrarily, yields go up when investors’ 
confidence on riskier investments is high, since the demand for treasuries falls. Thus, treasury 
yields are influenced by the interest rate environment, but also by investors’ expectations. 
Following the 2008 financial crisis, the Fed lowered interest rates to historically low levels, 
setting it between 0.00% and 0.25
1
. Those rates were kept until the end of 2015. After that, 
the Fed gradually raised it to 2.5%, responding to strong gdp growth and in order to stabilize 
the economy and avoid the rapid increase of inflation. Yet, in 2019 interest rates started going 
down again. In 2019, the Fed has already dropped its federal funds rate three times, in order to 
stimulate the economy and avoid an economic slowdown. In addition, President Donald 
Trump has been pressuring the Fed to lower rates, as he wants the same levels of interest rates 
that exist in Europe
2
. In Europe, the ECB has imposed negative interest rates on overnight 
deposits, meaning that banks are actually paying to lend money to the ECB. In addition, many 
European countries have negative treasury yields. This is true even in longer maturities, 
meaning that investors believe rates will increase soon.  
U.S. 10-year treasury yields have typically been above the federal funds rate, which makes 
sense as it has a longer maturity
3
. The evolution of both rates since 2000 is presented below: 
Exhibit 1. Fed Funds rate and U.S. 10-year Treasury yield (2000 – 2019) 
 
                                                          
1 U.S. Department of the Treasury. 2020. “Daily Treasury Yield Curve Rates”. Accessed January 2. 
https://www.treasury.gov/resource-center/data-chart-center/interest-rates/pages/TextView.aspx?data=yieldYear&year=2020 
2 CNBC. 2019. “What Trump’s call for 0% interest rates would mean for your wallet”. Accessed January 2. 
https://www.cnbc.com/2019/09/11/what-trumps-call-for-zero-interest-rates-would-mean-for-your-wallet.html 




Even if it clear that the Fed’s rate influences the 10-year yield (correlation of ~76.8%), during 
times of low interest rates (between 2002 and 2004 and since 2009) the 10-year yield is, on 
average, 2.09pps higher. In 2019, treasury yields have been decreasing, reaching historically 
low levels, following the Fed’s decisions to lower interest rates, but also due to the slowdown 
in economic growth and the long-lasting trade tensions between the world’s two largest 
economies (the U.S. and China), which affects investors’ confidence in the stock market.  
The impact on Johnson & Johnson’s valuation 
To measure the impact of changes in yields in J&J’s target price, three scenarios were 
defined: two in which future yields are higher and one in which they are lower. Bearing in 
mind that higher treasury yields lead to a higher WACC and lower share price, it is more 
important to address the risk of yields increasing, either due to changes in interest policies or 
market expectations. Still, as we have witnessed the U.S. President asking for lower interest 
rates, a scenario in which treasury yields are lower was performed. The impact on J&J’s price 
was measured through the DCF model. The scenarios for the future 10-year treasury yields 
(U.S.) were defined as follows: 
 3.39% - average yield between 2000 and 2019. 
 2.49% - average yield after the 2008 financial crisis (between 2009 and 2019). 
 1.46% - the lowest monthly value for the U.S. treasury yield (July, 2016). 
Finally, the WACC and target prices were computed. The return in 12 months was estimated 
assuming total dividends in 2020, equal to $3.95 per share. The result was the following: 
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Exhibit 2. Johnson & Johnson's Target Price 
Current Price: $145.87 Probability U.S. 10-year Yield WACC Target Price 12m return
Average since 2000 5% 3.39% 7.76% 107.22$         -24%
Average 2009 - 2018 20% 2.49% 6.89% 137.97$         -3%
Current 50% 1.92% 6.35% 166.00$         17%
Lowest 25% 1.46% 5.91% 197.25$         38%
Target Price 165.27$    
From this analysis, it was possible to conclude that the interest rate environment is, in fact, 
crucial for the determination of J&J’s fair value. With the return on the risk-free asset ranging 
from 1.46% and 3.39%, J&J’s fair price ranges from $107.22 to $197.25 (a $90 range). This 
shows how sensitive the DCF model is to its underlying WACC assumptions.  
As U.S. treasury yields are currently at historically low levels, one can argue that an increase 
in interest rates is a more likely scenario than interest rates decreasing even further. Still, this 
has not been the case in 2019, as the Federal Reserve as already lowered interest rates three 
times and the treasury yield depicts a downward trend. In addition, even if many believed 
interest in Europe would not stay negative for long, these rates have been around for quite 
some time. This, combined with President Donald Trump’s desire for lower interest rates, 
leads me to believe that probably treasury yields will not rise any time soon and may even 
decrease. Still, if the assumption was that the likelihood of treasury yields rising was the same 
of them going down (25% probability for each of those scenarios), a target price of $165.27 
would be attained. This leads to a 12-month return of 16%, with J&J currently being 




All things considered, I have verified that interest rates can highly impact Johnson & 
Johnson’s intrinsic value, as small variations in the underlying WACC assumptions may 
cause the company’s stock price to significantly diverge. The expected 12-month return for 
each scenario is given by: 
 U.S. 10-year Treasury yield = 3.39% - negative return of 24%. 
 U.S. 10-year Treasury yield = 2.49% - negative return of 3%.  
 U.S. 10-year Treasury yield = 1.92% (current) - positive return of 17%. 
 U.S. 10-year Treasury yield = 1.46% - positive return of 38%. 
Due to the current economic and political environments, I would predict a positive effect on 
J&J’s price to be more likely than a negative effect, as interest rates and treasury yields can 
decrease. Still, in the future, it is likely that interest rates will eventually rise again, and that 
may negatively impact J&J’s intrinsic value. Assuming that the probability of treasury yields 
rising in the future is equal to the probability of yields decreasing, the price target would be 
$165.27. This leads to a return of 16% over 12 months and reinforces the previous 
conclusion: buying J&J’s stock is a good investment, as it is currently being undervalued by 
the stock market. 
